{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:46:57Z","timestamp":1781239617005,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R146-A9508-16-S2"],"award-info":[{"award-number":["R146-A9508-16-S2"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00259-020-04704-2","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T17:06:04Z","timestamp":1581440764000},"page":"1496-1509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["In vivo imaging of cell proliferation in meningioma using 3\u2032-deoxy-3\u2032-[18F]fluorothymidine PET\/MRI"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6231-422X","authenticated-orcid":false,"given":"Asma","family":"Bashir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Binderup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Bitsch","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Broholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth","family":"Marner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Ziebell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e5re","family":"Fugleholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"4704_CR1","first-page":"231","volume":"5","author":"T Backer-Gr\u00f8ndahl","year":"2012","unstructured":"Backer-Gr\u00f8ndahl T, Moen BH, Torp SH. The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol. 2012;5:231\u201342.","journal-title":"Int J Clin Exp Pathol"},{"key":"4704_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803\u201320.","journal-title":"Acta Neuropathol"},{"key":"4704_CR3","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.3171\/FOC\/2008\/24\/5\/E3","volume":"24","author":"BE Pearson","year":"2008","unstructured":"Pearson BE, Markert JM, Fisher WS, et al. Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus. 2008;24:E3.","journal-title":"Neurosurg Focus"},{"key":"4704_CR4","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/S1470-2045(16)30321-7","volume":"17","author":"R Goldbrunner","year":"2016","unstructured":"Goldbrunner R, Minniti G, Preusser M, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17:e383\u201391.","journal-title":"Lancet Oncol"},{"key":"4704_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3171\/2016.11.JNS161170","volume":"129","author":"L Rogers","year":"2018","unstructured":"Rogers L, Zhang P, Vogelbaum MA, et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 059. J Neurosurg. 2018;129:35\u201347.","journal-title":"J Neurosurg"},{"key":"4704_CR6","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1016\/j.ejca.2012.05.001","volume":"48","author":"A Chalkidou","year":"2012","unstructured":"Chalkidou A, Landau DB, Odell EW, et al. Correlation between Ki-67 immunohistochemistry and 18F-Fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2012;48:3499\u2013513.","journal-title":"Eur J Cancer"},{"key":"4704_CR7","first-page":"1210","volume":"43","author":"JS Rasey","year":"2002","unstructured":"Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210\u20137.","journal-title":"J Nucl Med"},{"key":"4704_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00259-004-1611-0","volume":"32","author":"H Barthel","year":"2005","unstructured":"Barthel H, Perumal M, Latigo J, et al. The uptake of 3\u2032-deoxy-3\u2032-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging. 2005;32:257\u201363.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4704_CR9","first-page":"2681","volume":"63","author":"M Wagner","year":"2008","unstructured":"Wagner M, Seitz U, Buck A, et al. 3\u2032-[F-18]fluoro-3\u2032-deoxythymidine ([F-18]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res. 2008;63:2681\u20137.","journal-title":"Cancer Res"},{"key":"4704_CR10","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2967\/jnumed.108.060723","volume":"50","author":"H Wang","year":"2009","unstructured":"Wang H, Zhang J, Tian J, et al. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer. J Nucl Med. 2009;50:1857\u201364.","journal-title":"J Nucl Med"},{"key":"4704_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2967\/jnumed.111.089482","volume":"52","author":"JS Brockenbrough","year":"2011","unstructured":"Brockenbrough JS, Souquet T, Morihara JK, et al. Tumor 3\u2032-deoxy-3\u2032-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors. J Nucl Med. 2011;52:1181\u20138.","journal-title":"J Nucl Med"},{"key":"4704_CR12","doi-asserted-by":"publisher","first-page":"e58938","DOI":"10.1371\/journal.pone.0058938","volume":"8","author":"ET McKinley","year":"2013","unstructured":"McKinley ET, Ayers GD, Smith A, et al. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One. 2013;8:e58938.","journal-title":"PLoS One"},{"key":"4704_CR13","first-page":"2681","volume":"63","author":"CC Zhang","year":"2003","unstructured":"Zhang CC, Yan Z, Li W, et al. [18F]FLT-PET imaging does not always \u201clight up\u201d proliferating tumor cells. Clin Cancer Res. 2003;63:2681\u20137.","journal-title":"Clin Cancer Res"},{"key":"4704_CR14","first-page":"1948","volume":"46","author":"AH Jacobs","year":"2005","unstructured":"Jacobs AH, Thomas A, Kracht LW, et al. 18F-fluro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948\u201358.","journal-title":"J Nucl Med"},{"key":"4704_CR15","first-page":"1612","volume":"47","author":"M Muzi","year":"2006","unstructured":"Muzi M, Spence AM, O\u2019Sullivan F, et al. Kinetic analysis of 3\u2032-deoxy-3\u2019-18F-fluorothymidine in patients with gliomas. J Nucl Med. 2006;47:1612\u201321.","journal-title":"J Nucl Med"},{"key":"4704_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00259-006-0354-5","volume":"34","author":"C Schiepers","year":"2007","unstructured":"Schiepers C, Chen W, Dahlbom M, et al. (18)F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging. 2007;34:1003\u201311.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4704_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1023\/A:1015042227131","volume":"251","author":"A Blocher","year":"2002","unstructured":"Blocher A, Kuntzsch M, Wei R, Machulla HJ. Synthesis and labeling of 5-O-(4,4-dimethoxytrityl)-2,3\u2032-anhydrothymidine for [18F]FLT preparation. J Radioanal Nucl Chem. 2002;251:55\u20138.","journal-title":"J Radioanal Nucl Chem"},{"key":"4704_CR18","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00259-005-1813-0","volume":"32","author":"AF Shields","year":"2005","unstructured":"Shields AF, Briston DA, Chandupatla S, et al. A simplified analysis of [18F]3\u2032-deoxy-3\u2032-fluorothymidine metabolism and retention. Eur J Nucl Med Mol Imaging. 2005;32:1269\u201375.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4704_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fnins.2017.00453","volume":"11","author":"CN Ladefoged","year":"2017","unstructured":"Ladefoged CN, Andersen FL, Kj\u00e6r A, et al. RESOLUTE PET\/MRI attenuation correction for O-(2-18F-fluoroethyl)-L-tyrosine (FET) in brain tumor patients with metal implants. Front Neurosci. 2017;11:453.","journal-title":"Front Neurosci"},{"key":"4704_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/0271678X17691784","volume":"38","author":"MM Khalighi","year":"2018","unstructured":"Khalighi MM, Deller TW, Fan AP, et al. Image-derived input function estimation on a TOF-enabled PET\/MR for cerebral blood flow mapping. J Cereb Blood Flow Metab. 2018;38:126\u201335.","journal-title":"J Cereb Blood Flow Metab"},{"key":"4704_CR21","doi-asserted-by":"publisher","first-page":"10671","DOI":"10.18632\/oncotarget.3870","volume":"6","author":"P Domingues","year":"2015","unstructured":"Domingues P, Gonz\u00e1lez-Tablas M, Otero \u00c1, et al. Genetic\/molecular alterations of meningiomas and the signalling pathways targeted. Oncotarget. 2015;6:10671\u201388.","journal-title":"Oncotarget."},{"key":"4704_CR22","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.3171\/2018.1.FOCUS17754","volume":"44","author":"S Gupta","year":"2018","unstructured":"Gupta S, Linda W, Dunn IF. Medical management of meningioma in the era of precision medicine. Neurosurg Focus. 2018;44:E3.","journal-title":"Neurosurg Focus"},{"key":"4704_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0304-3835(88)90210-8","volume":"43","author":"C Carstens","year":"1988","unstructured":"Carstens C, Messe E, Zang KD, Blin N. Human KRAS oncogene expression in meningioma. Cancer Lett. 1988;43:37\u201341.","journal-title":"Cancer Lett"},{"key":"4704_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1750-3639.2009.00340.x","volume":"20","author":"D Barski","year":"2010","unstructured":"Barski D, Wolter M, Reifenberger G, Riemenschneider MJ. Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12. 3 and malignancy in meningiomas. Brain Pathol. 2010;20:623\u201331.","journal-title":"Brain Pathol"},{"key":"4704_CR25","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1038\/s41467-018-05931-w","volume":"9","author":"M Nagae","year":"2018","unstructured":"Nagae M, Kizuka Y, Mihara E, et al. Structure and mechanism of cancer-associated N-acetylglucosaminyltransferase-V. Nat Commun. 2018;9:3380.","journal-title":"Nat Commun"},{"key":"4704_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1023\/B:NEON.0000013474.01161.58","volume":"66","author":"M Okada","year":"2004","unstructured":"Okada M, Miyake K, Matsumoto Y, et al. Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas. J Neuro-Oncol. 2004;66:29\u201337.","journal-title":"J Neuro-Oncol"},{"key":"4704_CR27","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/cncr.22130","volume":"107","author":"AF Okuducu","year":"2006","unstructured":"Okuducu AF, Zils U, Michaelis SA, et al. Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. Cancer. 2006;107:1365\u201372.","journal-title":"Cancer."},{"key":"4704_CR28","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.2967\/jnumed.112.104729","volume":"53","author":"Y Yamamoto","year":"2012","unstructured":"Yamamoto Y, Ono Y, Aga F, et al. Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas. J Nucl Med. 2012;53:1911\u20135.","journal-title":"J Nucl Med"},{"key":"4704_CR29","first-page":"945","volume":"46","author":"W Chen","year":"2005","unstructured":"Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005;46:945\u201352.","journal-title":"J Nucl Med"},{"key":"4704_CR30","doi-asserted-by":"publisher","unstructured":"Galldiks N, Lohmann P, Albert NL, et al. Current status of PET imaging in neuro-oncology. Neuro-Oncology. 2019. https:\/\/doi.org\/10.1093\/noajnl\/vdz010.","DOI":"10.1093\/noajnl\/vdz010"},{"key":"4704_CR31","doi-asserted-by":"publisher","first-page":"e95830","DOI":"10.1371\/journal.pone.0095830","volume":"9","author":"M Nowosielski","year":"2014","unstructured":"Nowosielski M, Difranco MD, Putzer D, et al. An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLoS One. 2014;9:e95830.","journal-title":"PLoS One"},{"key":"4704_CR32","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/RLU.0b013e3181becfe0","volume":"34","author":"M Tripathi","year":"2009","unstructured":"Tripathi M, Sharma R, D\u2019Souza M, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET\/CT for metabolic imaging of low grade gliomas. Clin Nucl Med. 2009;34:878\u201383.","journal-title":"Clin Nucl Med"},{"key":"4704_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00259-012-2275-9","volume":"40","author":"A Shinomiya","year":"2013","unstructured":"Shinomiya A, Kawai N, Okada M, et al. Evaluation of 3\u2032-deoxy-3\u2032-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas. Eur J Nucl Med Mol Imaging. 2013;40:175\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4704_CR34","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987\u20139.","journal-title":"Nat Med"},{"key":"4704_CR35","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1097\/RLU.0000000000001229","volume":"41","author":"A Nikaki","year":"2016","unstructured":"Nikaki A, Prassopoulos V, Efthimiadou R, et al. FLT PET\/CT in a case of demyelinating disease. Clin Nucl Med. 2016;41:e342\u20135.","journal-title":"Clin Nucl Med"},{"key":"4704_CR36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1102\/1470-7330.2011.0020","volume":"11","author":"JL Holter","year":"2011","unstructured":"Holter JL, Thorp K, Smith ML, et al. [18F]Fluorothymidine PET imaging in the diagnosis of leptomeningeal involvement with diffuse large B-cell lymphoma. Cancer Imaging. 2011;11:140\u20133.","journal-title":"Cancer Imaging"},{"key":"4704_CR37","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/MAO.0000000000002272","volume":"40","author":"JM Anton-Rodriguez","year":"2019","unstructured":"Anton-Rodriguez JM, Lewis D, Djoukhadar I, et al. [18F]flurothymidine and [18F]flurodeoxyglucose PET imaging demonstrates uptake and differentiates growth in neurofibromatosis 2 related vestibular schwannoma. Otol Neurootol. 2019;40:826\u201335.","journal-title":"Otol Neurootol"},{"key":"4704_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/neuonc\/noy137","volume":"21","author":"RY Huang","year":"2019","unstructured":"Huang RY, Bi WL, Weller M, et al. Proposed response assessment and endpoints for meningioma clinical trials: report from the response assessment in neuro-oncology working group. Neuro-Oncol. 2019;21:26\u201336.","journal-title":"Neuro-Oncol."},{"key":"4704_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fonc.2018.00018","volume":"8","author":"NC Nguyen","year":"2018","unstructured":"Nguyen NC, Yee MK, Tuchayi AM, et al. Targeted therapy and immunotherapy response assessment with F-18-Flourothymidine positron-emission-tomography\/magnetic resonance imaging in melanoma brain metastasis: a pilot study. Front Oncol. 2018;8:18.","journal-title":"Front Oncol"},{"key":"4704_CR40","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1007\/s00259-009-1133-x","volume":"36","author":"JW Lee","year":"2009","unstructured":"Lee JW, Kang KW, Park SH, et al. 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging. 2009;36:1574\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4704_CR41","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s12149-018-1284-6","volume":"32","author":"K Mitamura","year":"2018","unstructured":"Mitamura K, Yamamoto Y, Norikane T, et al. Correlation of 18F-FDG and 11C-methionine uptake in PET\/CT with Ki-67 immunohistochemistry in newly diagnosed intracranial meningiomas. Ann Nucl Med. 2018;32:627\u201333.","journal-title":"Ann Nucl Med"},{"key":"4704_CR42","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11060-011-0759-2","volume":"107","author":"H Arita","year":"2012","unstructured":"Arita H, Kinoshita M, Okita Y, et al. Clinical characteristics of meningiomas assessed by 11C-methionine and 18F-fluorodeoxyglucose positron-emission tomography. J Neuro-Oncol. 2012;107:379\u201386.","journal-title":"J Neuro-Oncol"},{"key":"4704_CR43","first-page":"345","volume":"17","author":"T Ogawa","year":"1996","unstructured":"Ogawa T, Inugami A, Hatazawa J, et al. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol. 1996;17:345\u201353.","journal-title":"AJNR Am J Neuroradiol"},{"key":"4704_CR44","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00259-014-2934-0","volume":"42","author":"JF Cornelius","year":"2015","unstructured":"Cornelius JF, Stoffels G, Fil\u00df C, et al. Uptake and tracer kinetics of O-(2-(18)F-fluoroethyl)-L-tyrosine in meningiomas: preliminary results. Eur J Nucl Med Mol Imaging. 2015;42:459\u201367.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4704_CR45","first-page":"371","volume":"46","author":"M Muzi","year":"2005","unstructured":"Muzi M, Mankoff DA, Grierson JR, et al. Kinetic modeling of 3\u2032-deoxy-3\u2032-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med. 2005;46:371\u201380.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04704-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-020-04704-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04704-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T07:07:39Z","timestamp":1612940859000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-020-04704-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["4704"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-04704-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]},"assertion":[{"value":"28 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Scientific Health Ethics Committee of the Capital region, Copenhagen, Denmark (reference number: H-15006091) and was based on the Declaration of Helsinki II (2013) and the principles of \u201cgood clinical practices\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}